Drugs / 68Ga-exendin-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05662189 | Mar 2022 → Jul 2025 overdue | hyperinsulinism, prediabetes syndrome, type 1 diabetes mellitus, type 2 diabetes mellitus | Azienda Ospedaliero-Universitaria di Parma | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-exendin-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05662189 ↗ |
| Modality | Diagnostic / imaging agent | “Exendin-4 has been already labeled with a positron emitting nuclide and made amenable to PET imaging for diagnostic purposes.” NCT05662189 ↗ |